Fundraising Fox
/Companies
Sign in

AirNexis Therapeutics

Palo Alto, US · Founded 2024 · 4 known investors

Find your way into AirNexis Therapeutics

636 people in our graph can introduce you to the AirNexis Therapeutics team.

Sign up to see every warm intro you have to AirNexis Therapeutics

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the AirNexis Therapeutics team. We find them
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes you can't see from your own inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

Clinical-stage biopharmaceutical company developing novel inhaled therapies for COPD.

Biotech

Founders & leadership

JL
James LiExecutive
MFMaria Fardis
Maria FardisChief Executive OfficerVenture Partner at Frazier Life Sciences

Board

AC
Anna ChenBoard director
CW
Colin WalshBoard director
EC
Evan CaplanBoard director
JCJill Carroll
Jill CarrollBoard directorOperating Partner - Portfolio Value Creation at SR One Capital Management

Investors · 4

Longitude Capitallisted by Longitude CapitalMenlo Park · $10M – $30M

How we know: Longitude Capital's portfolio page · Not right? Tell us

OrbiMedlisted by OrbiMedNew York · $1M – $75M

How we know: OrbiMed's portfolio page · Not right? Tell us

SR One Capital Managementlisted by SR One Capital ManagementRedwood City

How we know: SR One Capital Management's portfolio page · a partner's Signal profile · Not right? Tell us

Funding

SEC filings, press & company announcements

$262M disclosed across 2 rounds · 2026

▶$62MraisedMar 2026 · 13 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Anna ChenDirector
  • Colin WalshDirector
  • Evan CaplanDirector
  • James LiExecutive Officer, Director
  • Jill CarrollDirector
  • Maria FardisExecutive Officer, Director
Offering amount
$200M
Amount sold
$62M
First sale
Jan 2026
Incorporated
Corporation, Delaware, 2024
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Frequently asked questions

What does AirNexis Therapeutics do?
Clinical-stage biopharmaceutical company developing novel inhaled therapies for COPD.
Who are AirNexis Therapeutics's investors?
AirNexis Therapeutics's investors include Frazier Life Sciences, Longitude Capital, OrbiMed, SR One Capital Management.
How much funding has AirNexis Therapeutics raised?
AirNexis Therapeutics has disclosed $262M raised across 2 rounds.
Where is AirNexis Therapeutics headquartered?
AirNexis Therapeutics is headquartered in Palo Alto, US.